Annovis Bio, Inc. · NYSE:ANVS
Annovis Bio — IPO Roadshow (May 2021)
25 slides from Annovis Bio's IPO roadshow presentation, May 21, 2021
Slide 1: Attacks Alzheimer's Disease and Neurodegeneration by Improving Axonal Transport
Attacks Alzheimer’s Disease and Neurodegeneration by Improving the Information Highway of the Nerve Cell Axonal Transport May 2021 Symbol: ANVS (NYSE American)
Slide 2: Forward-Looking Statements
FORWARD - LOOKING STATEMENTS Statements in this presentation contain “forward - looking statements” that are subject to substantial risks and uncertainties. Forward - looking statements contained in this presentation may be identified by the use of words such as “anticipate,” “expect,” “believe,” “w
Slide 3: Highlights
3 ▪ Annovis is developing drugs for Alzheimer's (AD) and Parkinson's disease (PD), including the orphan indication Alzheimer's in Down Syndrome (AD - DS) ▪ Lead compound - ANVS401 - in Phase 2a clinical trial, is the only drug to improve cognition in AD and motor function in PD patients, as recently
Slide 4: How Nerve Cells Work
NEUROTRANSITTERS THAT TRAVEL ACCROSS THE AXON Adrenaline Noradrenaline Dopamine HOW NERVE CELLS WORK In healthy nerve cells little packages containing neurotransmitters or nerve growth factors travel unimpaired from the cell body through the axon to the synapse. SOMA & CELL BODY DENDRITES Serotonin
Slide 5: Neurotoxic Proteins Impair Axonal Transport and Cause a Toxic Cascade
NEUROTOXIC PROTEINS IMPAIR AXONAL TRANSPORT AND CAUSE A TOXIC CASCADE ANVS401 IMPROVES AXONAL TRANSPORT AND IMPEDES THE TOXIC CASCADE IMPAIRED AXONAL TRANSPORT SLOWER SYNAPTIC TRANSMISSION INFLAMMATION DEATH OF NERVE CELLS LOSS OF COGNITIVE AND MOTOR FUNCTION IMPROVED AXONAL TRANSPORT INCREASED SYNA
Slide 6: Neurodegeneration Is an Axonal Transport Disease
NEURODEGENERATION IS AN AXONAL TRANSPORT DISEASE Axonal transport is responsible for: Normal Transport The Normal Flow and Speed of vesicles carrying BDNF across the axon. ▪ Neurotransmitters GABA (anxiety), ACh (cognition), dopamine (movement), serotonin (mood) ▪ Neurotrophic factors NGF, BDNF ▪ Al
Slide 7: Results in Animals
7 RESULTS IN ANIMALS Multiple animal studies showed that ANVS401 improved the affected function Function Animal Model Memory and learning (4) AD mice, DS mice, stroke mice, TBI rats Movement (2) PD mice, FTD mice Eyesight (1) Acute glaucoma rats
Slide 8: Two Phase 2 Clinical Trials
8 TWO PHASE 2 CLINICAL TRIALS AD Trial PD Trial CRO Parexel Therapeutic Area Early to Moderate AD Early to Moderate PD Phase 2 2 Patients 14 14 + 40 Sites 12 12 Country United States Design Double - Blind, Placebo - Controlled, Biomarker Study Endpoints Reversal of Toxic Cascade
Slide 9: Phase 2 Clinical Trial to Measure Reversal of the Toxic Cascade
PHASE 2 CLINICAL TRIAL IN AD AND PD TO MEASURE REVERSAL OF THE TOXIC CASCADE AND IMPROVEMENT IN BRAIN FUNCTION DECREASE IN NEUROTOXIC PROTEINS INCREASE IN NEUROTRANSMITTERS LOWERING OF INFLAMMATORY PROTEINS LOWERING OF NEURODEGENERATION MARKERS COGNITION AND MOTOR FUNCTION ENDPOINTS TARGET: PATHWAY:
Slide 10: Timeline of Phase 2 Clinical Trial in AD and PD
TIMELINE OF PHASE 2 CLINICAL TRIAL IN AD and PD Preliminary data commenced in 1Q2021 Start Up AD/PD Study August 2020 June/July 2021 August 2021 10 A meeting with the FDA to discuss the data from the AD and the PD study as well as from the chronic toxicology in rats and dogs is projected for Fall of
Slide 11: Reversal of Toxic Cascade
REVERSAL OF TOXIC CASCADE EXPECTED OUTCOME ACTUAL OUTCOME AD PD Level of neurotoxic proteins Axonal transport Inflammation Dead nerve cells Control proteins 0 Efficacy: Motor function Efficacy: Cognition REVERSAL OF TOXIC CASCADE D ata from first 14 AD and 14 PD patients 11 +++ p < 0.001 ++ p < 0.01
Slide 12: Efficacy in PD Patients – Speed & Coordination
EFFICACY IN PD PATIENTS – SPEED & COORDINATION Data from first 14 PD patients 30 35 40 45 50 55 0 25 BASELINE VS 25 DAYS 30 35 40 45 50 55 PLACEBO ANVS401 PLACEBO VS 401 0 0.5 1 1.5 2 2.5 3 0 25 Baseline vs 25 Days 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 placebo ANVS401 Placebo vs 401 Speed: Left - the compar
Slide 13: Lowering of Inflammation in PD Patients
LOWERING OF INFLAMMATION IN PD PATIENTS Data from first 14 PD patients 13 The trial measured four inflammatory markers that are prevalent in the brains of AD and of PD patients. Each of the inflammatory markers showed statistically significant reduction after 25 days of treatment with ANVS401 compar
Slide 14: Efficacy in AD Patients – ADAS-Cog11
EFFICACY IN AD PATIENTS – ADAS - Cog11 D ata from 14 AD patients 14 Within Data: From baseline to 25 days in the ANVS401 - treated group, ADAS - Cog11 improved by 4.4 points, a statistically significant improvement of 30% (p=0.04). Between Data: ANVS401 - treated group compared to placebo group at 2
Slide 15: Market Projections
1% 2% 4% 8% 16% 47% 60-65 65-70 70-75 75-80 80-85 85+ 15 MARKET PROJECTIONS Source: Alzheimer‘s Association 2014; Incidence of AD in Relation to Age Increase in Incidence with Aging of Population Annual sales potential for US and worldwide are over $100 billion dollars
Slide 16: Capitalization Table
Capitalization Table 16 Common Shares 6,947,269 Options (WAEP: $2.58) 1,107,598 Warrants (WAEP: $7.50) 4,800 Fully Diluted Shares Outstanding 8,059,667 Debt $0
Slide 17: Management and Advisory Team
MANAGEMENT AND ADVISORY TEAM Feng Chang, PhD, VP of Research Dr . Chang is an experienced neuroscientist with more than a decade of experience in neurodegenerative diseases, with broad scientific knowledge and hands - on experience . Prior to joining Annovis , she was a scientific solution consultan
Slide 18: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD 18 Sidney Strickland, PhD, Chairman Vice President and Dean for Educational Affairs and Research Professor, Patricia and John Rosenwald Laboratory of Neurobiology and Genetics at Rockefeller University. Dr. Strickland’s laboratory investigates how dysfunction of the circula
Slide 19: Board of Directors
19 Michael B . Hoffman Chairman Mr. Hoffman is the Founder and Managing Partner of Stone Capital Partners, a private equity firm focused on power and renewable energy. He was Partner of Riverstone, senior managing director at the Blackstone Group and managing director at Smith Barney, Harris Upham &
Slide 20: Investment Summary
INVESTMENT SUMMARY A novel approach to treat neurodegeneration is desperately needed ▪ The markets for AD and PD drugs are in the multibillions of dollars and growing ▪ Annovis has a novel approach to stop the course of AD and PD ▪ ANVS401 shows statistically significant improvements in Phase 2a cli
Slide 21: Change in Causes of Death from 2000 to 2018
CHANGE IN CAUSES OF DEATH FROM 2000 TO 2018 21 • Breast Cancer - 13% • Colon Cancer - 21% • Heart Disease - 21% • Stroke - 24% • HIV - 67% • Parkinson’s + 84% • Alzheimer’s + 112%
Slide 22: Annovis' Drug Attacks Multiple Neurotoxic Proteins
Chronic and acute brain insults lead to high levels of neurotoxic proteins, to inflammation and neurodegeneration Attacking one neurotoxic protein results in minimal effect ANVS401 is the only drug to attack multiple neurotoxic proteins simultaneously Amyloid β AD / PD - A β Targeting Compounds ANNO
Slide 23: Pipeline
PIPELINE 23 Therapy Diseases/Conditions PRE - CLINICAL IND PHASE I PHASE II PHASE III AD PD AD - DS FTD CTE TBI Stroke Advanced AD Oral drug for chronic indications Injectable drug for acute traumatic events Oral drug for advanced AD and dementia
Slide 24: Corporate Patent Estate
24 CORPORATE PATENT ESTATE Patent/Application Subject Matter Status Expiry Provisional ANVS401 to treat viral and bacterial infections of the brain, including Covid19 Pending 2041 PCT ANVS401 and 405 – Mechanism of Action for prevention and treatment of diseases Pending 2038 PCT ANVS405 - Acute brai
Slide 25: Contact Us
Improves THE FLOW of Axonal Transport in Alzheimer’s Disease and Neurodegeneration CONTACT US 1055 Westlakes Drive Suite 300 Berwyn, PA 19312 +1 (610) 727 - 3913 info@annovisbio.com Investor Relations Dave Gentry CEO, RedChip Companies +1 (407) 491 - 4498 dave@redchip.com www.annovisbio.com Symbol: